INBS · Intelligent Bio Solutions Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Management believes there is a material risk that the Company's cash and cash equivalents as of June 30, 2026, of approximately $3.99 million, will be insufficient to fund its current operating plan through at least the next 12 months from the issuance of these consolidated financial statements. Accordingly, the Company will be required to raise additional funds during the next 12 months. While the Company intends to obtain additional funding through equity or debt financings, strategic collaborations, or other arrangements, there can be no assurance that such funding will be available on acceptable terms, or at all. If the Company is unable to obtain additional financing when needed, it may be required to delay, reduce, or curtail the scope of its operations and development activities. In addition, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern, unless it can successfully meet the stated objectives and/or raise additional capital.”View the 10-K filed Aug 19, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $4.22M | $3.05M | $3.11M | $1.26M | $437.15K | $1.98M | $188.74K | |
| $2.17M | $1.81M | $1.69M | $930.2K | — | — | — | |
| $2.05M | $1.25M | $1.43M | $326.67K | — | — | — | |
| 48.63% | 40.85% | 45.81% | 25.99% | — | — | — | |
| $10.5M | $8.92M | $9.26M | $8.03M | $4.92M | $3.36M | $2.2M | |
| $10.5M | $8.92M | — | — | — | — | — | |
| $1.15M | $949.29K | $947.44K | $805.76K | $0 | — | — | |
| $1.16M | $970.12K | $974.36K | $814.48K | — | — | — | |
| $15.34M | $12.74M | $12.13M | $13.66M | $8.77M | $7.55M | $3.05M | |
| -$12.61M | -$10.68M | -$10.28M | -$12.6M | -$8.34M | -$5.57M | -$2.86M | |
| -299.11% | -349.85% | -330.46% | -1002.11% | -1907.11% | -281.42% | -1513.69% | |
| -$11.44M | -$9.71M | -$9.31M | -$11.78M | — | — | — | |
| $10.74K | $26.34K | $167.14K | — | — | — | — | |
| $110.33K | $101.52K | $84.82K | — | — | — | — | |
| $139.41K | $74.27K | $92.24K | $1.93M | $2900 | -$1.49M | -$335.96K | |
| — | — | — | — | — | -$135.69K | $121.69K | |
| — | — | — | — | — | -$135.69K | $121.69K | |
| — | — | — | — | — | -$7.06M | -$3.19M | |
| -$12.43M | -$10.57M | -$10.16M | -$10.63M | -$8.31M | -$7.04M | -$3.16M | |
| -294.91% | -346.23% | -326.4% | -845.89% | -1900.06% | -355.33% | -1676.23% | |
| -$37.7K | -$36.15K | -$34.17K | -$32.84K | -$27.93K | -$22.92K | -$29.17K | |
| -$12.65M | -$10.18M | -$10.29M | -$10.42M | -$8.43M | -$7.33M | -$3.31M | |
| USD/shares | -$8.44 | -$20.04 | -$63.80 | -$1,270.00 | -$1,359.60 | -$1,632.00 | — |
| USD/shares | -$8.44 | -$20.04 | -$63.80 | -$1,270.00 | -$1,359.60 | — | — |
| shares | 1.47M | 527.36K | 159.27K | 8371.7 | 6110.525 | 4339.5358 | 3545.9704 |
| shares | 1.47M | 527.36K | 159.27K | 8371.7 | 6110.525 | 4339.5358 | 3545.9704 |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Notes payable, including current maturities | 2026-06-30 | USD 0 | 10-K filed 2026-08-19 |
| Operating lease liabilities | 2026-06-30 | USD 1,819,160 | 10-K filed 2026-08-19 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 53 similar-size Medical Devices companies (of 150 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| United Kingdom | $4,153,759 | $2,868,027 | $2,894,197 | $1,061,191 |
| Other Country | $40,199 | $132,700 | $162,222 | $189,190 |
| Asia Pacific | $12,467 | $29,167 | $43,955 | — |
| Americas | $8,750 | $22,638 | $11,407 | — |
| Australia | — | — | — | $6,491 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Sales of Goods Cartidges | $2,485,563 | $1,762,153 | $1,549,409 | $724,304 |
| Sales of Goods Readers | $902,263 | $711,737 | $938,897 | $335,863 |
| Other Sales Accessories | $827,349 | $578,642 | — | — |
| Other Sales | — | — | $623,475 | $196,705 |